Provexis (AQSE:PXS.GB) Current Accrued Expense : £0.00 Mil (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Provexis Current Accrued Expense?

Provexis's Current Accrued Expense for the quarter that ended in Sep. 2024 was £0.00 Mil.

Provexis Current Accrued Expense Historical Data

The historical data trend for Provexis's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provexis Current Accrued Expense Chart

Provexis Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Current Accrued Expense

Get a 7-Day Free Trial

Provexis Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Provexis Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Provexis Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Provexis's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Provexis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Provexis PLC (AQSE:PXS.GB) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

PXS:UK

Address

2 Blagrave Street, I Ford, Reading, Berkshire, GBR, RG1 1AZ

Website

https://www.provexis.com

Provexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.

Provexis Headlines

No Headlines